BCL2L12 and central nervous system cancer: The particles can cross the BBB through targeting class A scavenger receptors [106], and they are anticipated to reduce the Bcl2L12 expression and thus sensitize glioma toward therapy-induced apoptosis by enhancing effector caspase and p53 activity.